当前位置:首页 - 行情中心 - 东宝生物(300239) - 财务分析 - 利润表

东宝生物

(300239)

  

流通市值:28.96亿  总市值:29.15亿
流通股本:5.90亿   总股本:5.94亿

利润表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、营业总收入414,692,385.37190,525,037.37745,307,726.02532,797,977.19
  营业收入414,692,385.37190,525,037.37745,307,726.02532,797,977.19
二、营业总成本375,655,075.35168,542,826.28679,496,993.61479,925,097.45
  营业成本323,126,889.12144,255,143.98571,236,707.7402,128,895.05
  税金及附加6,560,326.842,793,272.1911,319,719.738,121,413.38
  销售费用9,840,988.494,877,689.2219,025,129.3913,505,319.55
  管理费用24,513,681.3710,970,426.9151,175,787.9936,123,934.77
  研发费用10,849,336.155,268,894.4425,481,838.9618,907,749.32
  财务费用763,853.38377,399.541,257,809.841,137,785.38
  其中:利息费用1,716,014.93855,955.034,011,729.683,151,033.47
  其中:利息收入1,361,269.46644,074.12,775,997.221,980,268.15
三、其他经营收益
  加:投资收益-969,650.52-650,492.84-2,861,860.37-2,163,655.2
  资产处置收益26,502.4926,172.58-93,367.15-75,476.56
  资产减值损失(新)-2,943,770.1-2,381,654.83-15,126,490.31-4,747,143.37
  信用减值损失(新)1,303,076.35580,869.45-876,562.79369,080.85
  其他收益5,284,057.163,028,983.6312,848,944.239,123,188.45
四、营业利润41,737,525.422,586,089.0859,701,396.0255,378,873.91
  加:营业外收入532,623.7522,4803,064,518.06735,566.53
  减:营业外支出20,150.99868.7846,118.92219,346.28
五、利润总额42,249,998.1123,107,700.3861,919,795.1655,895,094.16
  减:所得税费用4,845,973.683,413,627.177,584,386.187,447,458.66
六、净利润37,404,024.4319,694,073.2154,335,408.9848,447,635.5
(一)按经营持续性分类
  持续经营净利润37,404,024.4319,694,073.2154,335,408.9848,447,635.5
(二)按所有权归属分类
  归属于母公司股东的净利润37,404,024.4319,694,073.2154,337,306.9148,449,538.05
  少数股东损益---1,897.93-1,902.55
  扣除非经常损益后的净利润33,601,447.6117,298,974.1544,161,488.2642,055,914.73
七、每股收益
  (一)基本每股收益0.060.030.090.08
  (二)稀释每股收益0.060.030.090.08
九、综合收益总额37,404,024.4319,694,073.2154,335,408.9848,447,635.5
  归属于母公司股东的综合收益总额37,404,024.4319,694,073.2154,337,306.9148,449,538.05
  归属于少数股东的综合收益总额---1,897.93-1,902.55
公告日期2026-08-242026-04-242026-03-302025-10-29
审计意见(境内)标准无保留意见
TOP↑